Diffusion Imaging in Acute Auto-immune Encephalitis

NCT04339205 | Unknown

• 1 other identifier: Imaging study
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this non randomised retrospective study is to investigate the imaging (MRI) of auto-immune encephalitis at presentation, especially in diffusion-weighted sequences. Indeed, few series describe the MRI aspect of auto-immune at their beginning. Recognize early MRI abnormalities seen in auto-immune encephalitis could help reduce the time to positive diagnosis and improve the therapeutic management.

Conditions

Auto-immune Encephalitis

Keywords

MRI

Outcome Measures

Primary Outcomes (1)

• MRI characterization, especially in Diffusion-weighted magnetic resonance imaging (DWI-MRI), of auto-immune encephalitis at presentation.

  The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed. At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium. The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain. We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not.

  at following-up until 24 months

Interventions

Analysis of every MRI at presentation of the symptoms and then over a period of 3 to 24 months if available. OTHER

The radiologist will analyze the MRI of patients with proved auto-immune encephalitis realized at presentation of the symptoms. If available, the following-up MRIs will also be analyzed. At each assessment, four MRI sequences will be studied : diffusion, T2-weighted, susceptibility sensitive sequences, and T1 weighted after contrast enhanced with gadolinium. The radiologist will analyse the signal abnormalities, their localisation and the trophicity of the brain. We will then correlate the following clinical data collected for patients : age, sex, clinical presentation, clinical evolution, and tumor associated or not.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with auto-immune encephalitis

You may qualify if:

• Auto-immune encephalitis proved by biological results (blood and/or CSF sample)

You may not qualify if:

• No MRI available

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hospices Civils de Lyon

Pierre-Bénite, 69310, France

RECRUITING

Central Study Contacts

François cotton, phd

CONTACT

04 78 56 91 00; francois.cotton@chu-lyon.fr

Géraldine PICARD

CONTACT

04 72 35 58 42; geraldine.picard@chu-lyon.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2020
• First Posted: April 9, 2020
• Study Start: February 1, 2020
• Primary Completion: March 1, 2020
• Study Completion: July 1, 2020
• Last Updated: July 1, 2020

Record last verified: 2020-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)